J Drugs Dermatol. 2022 Mar 1;21(3):313-314. doi: 10.36849/JDD.6699.
Perifolliculitis capitis abscedens et suffodiens or dissecting cellulitis (DC) is a rare and chronic disease with a predilection for the occipital, vertex, and parietal scalp. DC is characterized by multinodular lesions with purulent drainage and sinus tract formation. It is classically seen in middle-aged males of African descent. The etiology of the disease is unknown; however, leading theories suggest that stasis associated with follicular occlusion begets bacterial infection and follicular destruction with a subsequent granulomatous and neutrophilic response.1 This is supported by the suppurative nature of the disease and its association with acne conglobota, pilonidal cysts, and hidradenitis suppurativa. These conditions are thought to have a shared etiology and are also widely accepted as being due to follicular occlusion.1 The approach to treatment of DC is varied as there is no current consensus on management. We present the case of risankizumab, an IL-23 inhibitor, used to successfully treat DC. J Drugs Dermatol. 2022;21(3): doi:10.36849/JDD.6699.
匐行性回状毛囊黏蛋白病和脱发性蜂窝织炎（DC）是一种罕见的慢性疾病，好发于枕部、顶部和顶颞部头皮。DC 的特征是多发性结节，伴有脓性分泌物和窦道形成。它通常发生在非洲裔中年男性中。该病的病因不明；然而，主要理论认为，与滤泡阻塞相关的淤滞会导致细菌感染和滤泡破坏，随后出现肉芽肿和中性粒细胞反应。1 这与疾病的化脓性质及其与聚合性痤疮、藏毛窦和化脓性汗腺炎的关联相一致。这些疾病被认为具有共同的病因，也被广泛认为是由于滤泡阻塞引起的。1 DC 的治疗方法多种多样，因为目前对其管理尚无共识。我们介绍了 IL-23 抑制剂 risankizumab 的病例，该药物成功治疗了 DC。J Drugs Dermatol. 2022;21(3): doi:10.36849/JDD.6699.
